Galecto Inc (NASDAQ:GLTO) — Market Cap & Net Worth
Market Cap & Net Worth: Galecto Inc (GLTO)
Galecto Inc (NASDAQ:GLTO) has a market capitalization of $1.47 Billion ($1.47 Billion) as of August 6, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #7264 globally and #2193 in its home market, demonstrating a -4.72% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Galecto Inc's stock price $24.45 by its total outstanding shares 60240072 (60.24 Million). Review GLTO cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
Galecto Inc Market Cap History: 2020 to 2026
Galecto Inc's market capitalization history from 2020 to 2026. Data shows change from $18.84 Billion to $1.47 Billion (-38.94% CAGR).
Index Memberships
Galecto Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.48 Trillion | 0.06% | #204 of 976 |
|
NASDAQ Composite
IXIC
|
$40.85 Trillion | 0.00% | #808 of 3165 |
Weight: Galecto Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Galecto Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Galecto Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of GLTO by Market Capitalization
Companies near Galecto Inc in the global market cap rankings as of August 6, 2026.
Key companies related to Galecto Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #426 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #546 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #570 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $484.83 |
| #426 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $768.58 |
| #546 | Argen-X | BR:ARGX | $49.55 Billion | €748.60 |
| #570 | UCB SA | BR:UCB | $47.34 Billion | €229.20 |
Galecto Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Galecto Inc's market cap moved from $18.84 Billion to $ 1.47 Billion, with a yearly change of -38.94%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.47 Billion | +6.26% |
| 2025 | $1.39 Billion | +394.84% |
| 2024 | $280.12 Million | -74.17% |
| 2023 | $1.08 Billion | -37.39% |
| 2022 | $1.73 Billion | -62.05% |
| 2021 | $4.56 Billion | -75.78% |
| 2020 | $18.84 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 6th, 2026 the market cap of Galecto Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.47 Billion USD |
| MoneyControl | $1.47 Billion USD |
| MarketWatch | $1.47 Billion USD |
| marketcap.company | $1.47 Billion USD |
| Reuters | $1.47 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Galecto Inc
Damora Therapeutics, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. It develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. The comp… Read more